Related Experiment Videos
[Serological evaluation of immunization against measles with 2 doses administered at 6 and 11 months of age: a
C S Pannuti1, V A de Souza, H K Sato
1Instituto de Medicina Tropical de São Paulo (LIM-52, HC FMUSP), Brasil.
Insights
A two-dose measles vaccination schedule at 6 and 11 months showed high seroconversion rates, indicating efficacy in infants. This approach may help control measles in regions with early-onset cases.
Area of Science:
- Immunology
- Vaccinology
- Pediatrics
Context:
- Measles remains a significant public health concern globally.
- Early childhood measles infections pose risks, particularly in regions with high incidence before nine months of age.
- Evaluating alternative vaccination schedules is crucial for effective measles control.
Purpose:
- To assess the serologic efficacy of a two-dose measles vaccination schedule administered at 6 and 11 months of age.
- To determine measles antibody seroconversion rates using indirect immunofluorescence technique (IFA) and ELISA.
- To evaluate the potential of this schedule as an alternative for measles control.
Summary:
- A prospective study evaluated a two-dose measles vaccination schedule (BIKEN CAM 70) at 6 and 11 months.
- Seroconversion rates were high: 88.5% by IFA and 96.8% by ELISA, 6-12 months post-second dose.
- No measles cases were reported during the study.
Impact:
- The findings suggest that a two-dose measles vaccination schedule at 6 and 11 months is serologically effective.
- This schedule could be a valuable strategy for measles control in areas with early-onset infections.
- The study provides evidence supporting optimized pediatric vaccination protocols for infectious disease prevention.
Abstract:
A prospective study was designed to evaluate the serologic efficacy of a two dose measles vaccination schedule, at 6 months and 11 months of age. Infants were given a further attenuated measles virus vaccine (BIKEN CAM 70, Fundação Oswaldo Cruz) and serum samples were tested for measles antibodies using the indirect immunofluorescence technique (IFA) and ELISA. Seroconversion rates 6 to 12 months (mean of 8.0 +/- 1.7 months) following the second dose of measles vaccine were 88.5% (85/96) by IFA and 96.8% (93/96) by ELISA. No measles cases were reported during the study period. In regions where a significant proportion of measles cases occurs before nine months of age, vaccination with a two doses schedule, at 6 and 11 months of age, may represent an alternative for measles control.